Publication:
Subgroup Analysis Based on Cytogenetic Risk in Patients With Relapsed or Refractory Multiple Myeloma in the CANDOR Study

Simple item page
dc.authorwosidMollee, Peter/A-6677-2012
dc.authorwosidKim, Jin/I-6927-2019
dc.authorwosidRosinol, Laura/Cah-3175-2022
dc.authorwosidTouzeau, Cyrille/L-2430-2015
dc.authorwosidHajek, Roman/I-6639-2017
dc.authorwosidUsmani, Saad/Hci-4676-2022
dc.contributor.authorLandgren, Ola
dc.contributor.authorWeisel, Katja
dc.contributor.authorRosinol, Laura
dc.contributor.authorTouzeau, Cyrille
dc.contributor.authorTurgut, Mehmet
dc.contributor.authorHajek, Roman
dc.contributor.authorUsmani, Saad Z.
dc.contributor.authorIDMollee, Peter/0000-0002-8537-1198
dc.contributor.authorIDLandgren, Ola/0000-0001-6485-4839
dc.contributor.authorIDHajek, Roman/0000-0001-6955-6267
dc.contributor.authorIDRosiñol, Laura/0000-0002-2534-9239
dc.contributor.authorIDKim, Jin Seok/0000-0001-8986-8436
dc.contributor.authorIDTouzeau, Cyrille/0000-0003-0275-2575
dc.contributor.authorIDUsmani, Saad/0000-0002-5484-8731
dc.date.accessioned2025-12-11T01:41:13Z
dc.date.issued2022
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Landgren, Ola] Sylvester Comprehens Canc Ctr, Div Hematol, Miami, FL USA; [Weisel, Katja] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & BMT, Hamburg, Germany; [Rosinol, Laura] IDIBAPS, Hosp Clin, Barcelona, Spain; [Touzeau, Cyrille] Ctr Hosp Univ Nantes, Serv Hematol Clin, Nantes, France; [Turgut, Mehmet] Ondokuz Mayis Univ, Div Hematol, Dept Internal Med, Fac Med, Samsun, Turkey; [Hajek, Roman] Univ Hosp Ostrava, Dept Haematooncol, Ostrava, Czech Republic; [Hajek, Roman] Univ Ostrava, Dept Haematooncol, Fac Med, Ostrava, Czech Republic; [Mollee, Peter] Princess Alexandra Hosp, Dept Haematol, Brisbane, Qld, Australia; [Mollee, Peter] Univ Queensland, Sch Med, Brisbane, Qld, Australia; [Kim, Jin Seok] Yonsei Univ, Severance Hosp, Coll Med, Seoul, South Korea; [Shu, Natalie] Parexel, Chengdu, Peoples R China; [Hu, Xuguang; Li, Chuang] Amgen Inc, Thousand Oaks, CA 91320 USA; [Usmani, Saad Z.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USAen_US
dc.descriptionMollee, Peter/0000-0002-8537-1198; Landgren, Ola/0000-0001-6485-4839; Hajek, Roman/0000-0001-6955-6267; Rosiñol, Laura/0000-0002-2534-9239; Kim, Jin Seok/0000-0001-8986-8436; Touzeau, Cyrille/0000-0003-0275-2575; Usmani, Saad/0000-0002-5484-8731en_US
dc.description.abstractCANDOR compared the safety/efficacy of carfilzomib with dexamethasone and daratumumab (KdD) to carfilzomib with dexamethasone (Kd) in adults with relapsed/refractory multiple myeloma (RRMM). This CANDOR subgroup analysis evaluated outcomes based on cytogenetic risk. Overall response rates (KdD vs. Kd) were 81% versus 56% in high-risk and 87% versus 79% in standard-risk groups. Median progression-free survival was 11.2 versus 7.4 months in high-risk (hazard ratio, 0.56 [95% CI, 0.34, 0.93]) and not reached versus 16.6 months in standard-risk groups (0.56 [95% CI, 0.39, 0.80]). These data support the efficacy of KdD in RRMM treatment, including in patients with high-risk cytogenetics.en_US
dc.description.sponsorshipAmgen Inc.; National Cancer Institute [P30CA240139] Funding Source: NIH RePORTERen_US
dc.description.sponsorshipThis work was supported by Amgen Inc.en_US
dc.description.woscitationindexScience Citation Index Expanded
dc.identifier.doi10.1111/bjh.18233
dc.identifier.endpage993en_US
dc.identifier.issn0007-1048
dc.identifier.issn1365-2141
dc.identifier.issue6en_US
dc.identifier.pmid35608261
dc.identifier.scopusqualityQ1
dc.identifier.startpage988en_US
dc.identifier.urihttps://doi.org/10.1111/bjh.18233
dc.identifier.urihttps://hdl.handle.net/20.500.12712/45345
dc.identifier.volume198en_US
dc.identifier.wosWOS:000801014600001
dc.identifier.wosqualityQ1
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofBritish Journal of Haematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRelapsed or Refractory Multiple Myelomaen_US
dc.subjectProteasome Inhibitoren_US
dc.subjectCarfilzomiben_US
dc.subjectCytogeneticsen_US
dc.titleSubgroup Analysis Based on Cytogenetic Risk in Patients With Relapsed or Refractory Multiple Myeloma in the CANDOR Studyen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu